ECOG-ACRIN Cancer Research Group

ECOG-ACRIN Cancer Research Group Biomarker-driven research involving adults who have or are at risk of developing cancer

ComboMATCH Treatment Trial E5, led by Kristen Spencer, DO, MPH of and Dustin Deming, MD of , is a randomized phase 2 s...
04/06/2026

ComboMATCH Treatment Trial E5, led by Kristen Spencer, DO, MPH of and Dustin Deming, MD of , is a randomized phase 2 study of sotorasib with or without panitumumab in advanced solid tumors. Learn more here: https://bit.ly/combomatch-e5

EA7211/STRASS 2, led in the US by Dr. Kenneth Cardona, is the second randomized study ever performed in retroperitonea...
04/06/2026

EA7211/STRASS 2, led in the US by Dr. Kenneth Cardona, is the second randomized study ever performed in retroperitoneal soft tissue & is enrolling patients in the US, Europe, Canada, Australia, New Zealand, & Japan! Learn more: https://bit.ly/EA7211

EA1241, led by Dr. Joseph Sparano of , is a companion study for patients who previously took part in either the TAILORx ...
04/06/2026

EA1241, led by Dr. Joseph Sparano of , is a companion study for patients who previously took part in either the TAILORx (PACCT-1) or RxPONDER (S1007) breast cancer trials. Learn more: https://bit.ly/EA1241

: Don’t miss the newest round-up of recently published findings from ECOG-ACRIN Cancer Research Group . See key resu...
04/03/2026

: Don’t miss the newest round-up of recently published findings from ECOG-ACRIN Cancer Research Group . See key results and why they matter:

The latest findings in breast cancer, cancer care delivery research, head and neck cancer, leukemia, and radiation therapy

Clinical trial MM1OA-EA02, led by Dr. Jessica Altman of the Lurie Cancer Center, aims to improve results for older adult...
04/03/2026

Clinical trial MM1OA-EA02, led by Dr. Jessica Altman of the Lurie Cancer Center, aims to improve results for older adults with acute myeloid leukemia (AML). Learn more: https://bit.ly/mm1oa-ea02-study

Do you have newly diagnosed glioblastoma? If so, you may be able to participate in this study of a new treatment approac...
04/03/2026

Do you have newly diagnosed glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: https://bit.ly/gable-trial

In clinical trial EA2222/PUMP, investigators are testing pump chemotherapy in addition to standard-of-care (SOC) chemoth...
04/02/2026

In clinical trial EA2222/PUMP, investigators are testing pump chemotherapy in addition to standard-of-care (SOC) chemotherapy versus SOC chemotherapy alone for patients with unresectable colorectal cancer liver metastases. For more: https://bit.ly/ea2222-pump

Monika Joshi, MD and Petros Grivas, MD, PhD are leading clinical trial EA8231, a phase 3 randomized trial comparing the ...
04/02/2026

Monika Joshi, MD and Petros Grivas, MD, PhD are leading clinical trial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemotherapy in patients with advanced urothelial cancer. https://bit.ly/ea8231-study

Clinical study EA3191 is testing a new treatment approach for patients with squamous cell carcinoma of the head and neck...
04/02/2026

Clinical study EA3191 is testing a new treatment approach for patients with squamous cell carcinoma of the head and neck (HNSCC) that has come back after initial therapy. Learn more: https://bit.ly/ea3191-study

In clinical trial EA7222, investigators are testing doxorubicin plus pembrolizumab vs. doxorubicin alone for patients w...
04/01/2026

In clinical trial EA7222, investigators are testing doxorubicin plus pembrolizumab vs. doxorubicin alone for patients with advanced undifferentiated pleomorphic sarcoma (UPS). For more information: https://bit.ly/EA7222

EA6244, led by Dr. Yana Najjar of UPMC Hillman Cancer Center, is testing a less invasive treatment approach for older ...
04/01/2026

EA6244, led by Dr. Yana Najjar of UPMC Hillman Cancer Center, is testing a less invasive treatment approach for older adults with early-stage . Learn more: https://bit.ly/ea6244-study

Do you have advanced has become worse following treatment, or advanced cancer for which no standard treatment exists? ...
04/01/2026

Do you have advanced has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the study. Learn more: http://bit.ly/ComboMATCH

Address

Philadelphia, PA

Telephone

+12157893631

Website

http://linktr.ee/ecog_acrin

Alerts

Be the first to know and let us send you an email when ECOG-ACRIN Cancer Research Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

We design and conduct cancer clinical trials, which are available to patients at nearly 1,200 member cancer centers and community hospitals in the US and internationally. We focus our research on adults who have or are at risk of developing cancer. The group is dedicated to achieving advances in all aspects of cancer care across all types of cancer. Our goal is to reduce the burden of cancer and improve the quality of life and survival in patients. Our primary source of funding is the National Cancer Institute, part of the National Institutes of Health.